PRP, exosomes, dutasteride, and minoxidil, delivered together as an integrated treatment series. The published evidence on combined regenerative protocols is one of the more interesting developments in non-surgical hair restoration in the last five years. Dr. Jones has undergone the treatment personally before bringing it into the practice.
The combined regenerative protocol integrates four therapies that each have their own evidence base, delivered as a coordinated treatment series rather than as isolated interventions.
Platelet-rich plasma (PRP). Your own platelets, concentrated by centrifuge and re-introduced into the scalp at the level of the follicle. The platelets release growth factors that support follicular activity. Full background on the PRP page.
Exosomes. Cell-derived signalling vesicles that carry growth factors and other regenerative messengers. Where the science currently sits is covered on the exosomes page.
Dutasteride. A more potent 5-alpha-reductase inhibitor than finasteride, used to block DHT formation at the follicle. In the combined protocol, dutasteride is delivered directly into the dermal layer rather than taken orally, which keeps systemic exposure low while putting the drug exactly where it needs to act.
Minoxidil sulfate. The active metabolite of minoxidil, which is what the follicle actually responds to. Delivering minoxidil sulfate directly avoids the conversion step that some patients perform poorly, and gets effective concentration to the follicle without the topical absorption ceiling.
The four agents are administered together in a series of monthly sessions, typically three to five depending on response, then maintenance afterward.
Topical hair-loss treatments hit a real ceiling. The stratum corneum, the outermost layer of skin, is a barrier evolution built specifically to keep substances out. Most of what you apply to your scalp never reaches the follicle in meaningful concentration, and what does reach it comes in unpredictable peaks and troughs.
The combined protocol uses controlled intradermal infusion to deposit the medications at the reticular dermis, the layer where follicular papillae actually live. The technique creates dense arrays of microchannels in the scalp while simultaneously infusing the prepared solution. Each pass deposits a small, even amount of medication exactly where it needs to act.
The microneedling itself is part of the therapy. Controlled micro-injury triggers a cascade of wound-healing signals, including platelet-derived growth factor and vascular endothelial growth factor, that stimulate the follicle independently of the drugs being delivered. Stem cells in the follicular bulge are activated, and the Wnt signalling pathway (essential for transitioning follicles into the active growth phase) is upregulated.
The combination of mechanical stimulation and direct dermal drug delivery is what the recent literature in the International Society of Hair Restoration Surgery’s forum has called the combined regenerative approach. It is meaningfully different from any of the agents used alone.
The published evidence for combined regenerative protocols delivered by intradermal infusion is recent and growing. Two illustrative findings from the literature:
In a cohort of fifteen men treated with monthly dutasteride and minoxidil sulfate microinfusion, more than half achieved over 10% measured increase in scalp regrowth. A subsequent protocol that added supporting agents and extended the series to five sessions reported a median regrowth of 26.5%, with the majority of patients surpassing the 10% improvement threshold.
A 2025-2026 study in Hair Transplant Forum International (the journal of the International Society of Hair Restoration Surgery) reported on a five-patient cohort treated with a four-agent combined regenerative protocol. Trichoscopy measured average density gains above 46% and shaft thickness gains above 62% across scalp regions, with statistically significant within-patient improvements in 11 of 12 measured parameters.
These results are encouraging but should be read in context. The published cohorts are small. The agent combinations vary between studies. Larger randomised trials are needed before this can be called a standard of care. What can be said honestly: the early evidence is more compelling than for any single one of these agents used in isolation.
The combined regenerative protocol fits patients with early-to-moderate androgenetic loss who still have functional follicles in the affected area. The treatment supports follicles that are present and partially active. It does not regrow hair from follicles that have already been lost.
Strong candidates. Early to moderate male or female pattern loss. Patients on (or considering) oral finasteride who want to layer in stronger follicular support. Patients who have plateaued on oral medication alone. Patients who have had a transplant and want to protect both transplanted and native hair during the early growth window.
Not the right fit. Patients with late-stage loss where most follicles in the affected area have already been lost. Patients with active scarring alopecias. Patients with bleeding disorders, certain cardiovascular comorbidities, or contraindications to any of the included drugs (notably dutasteride in pregnancy).
Like every treatment we offer, candidacy starts with photos. If the protocol is not a good match for your case, you will hear that in the assessment along with what the better path looks like.
New non-surgical treatments arrive at the practice on a single rule. The published evidence has to be credible, and Dr. Jones has to be willing to use the treatment himself before offering it to a patient.
Dr. Jones underwent the combined regenerative protocol personally. He saw the result on his own scalp and his own measurements. The decision to offer it at Toronto.Hair followed that, not the other way around.
Most clinics do not offer the four agents together. PRP is widely available. Exosomes are increasingly common. Dutasteride is usually prescribed orally. Minoxidil is usually applied topically or taken orally. Combining all four in a single integrated protocol, delivered by intradermal infusion, requires sourcing, compounding, equipment, and a clinical framework most practices do not have set up. That is part of why most clinics offer one of these in isolation.
We added it because the evidence is strong enough, the safety profile is good, and the clinical team is set up to deliver it correctly. We did not add it because it is a marketing opportunity.
The session. Scalp is cleansed and prepared. Local anaesthesia is delivered as a ring block to keep the procedure comfortable. The combined solution is infused across the treatment area, with sessions running about an hour. You will see faint pinpoint marks on the scalp afterward (the technique’s clinical endpoint), which resolve within a day or two.
Aftercare. Mild redness and light flaking for two to four days. Gentle cleansing can begin after twelve hours. Avoid strenuous exercise, heat exposure, and swimming for twenty-four hours. Existing topical or oral therapies usually resume the next day.
The series. Three to five monthly sessions, then maintenance afterward at a frequency tailored to your response. Photographic and trichoscopic tracking at standardised intervals lets us measure what is actually changing.
Side effects. Transient erythema and discomfort are expected. No infections or scarring have been reported in the published cohorts. Systemic absorption appears limited, though a small drop in diastolic blood pressure has been observed in some patients on the protocol. Patients with cardiovascular conditions are assessed accordingly.
Send photos for review. Dr. Jones will assess whether you are a strong candidate for the combined regenerative protocol, or whether another path makes more sense for your situation. Written response within forty-eight hours.